Opnurasib (10-100 mg/kg, Orally, daily for 14 days) shows antitumor activity in KRAS G12C-mutated CDX models[2].
Opnurasib (Orally, 100 mg/kg, daily (JDQ443) + 7.5 mg/kg, twice daily (TNO155), for 36 days) shows greater cell growth inhibition or cell killing compared with single-agent JDQ443 when combined with TNO155[2].
Opnurasib generates categorical antitumor responses in PDX models of NSCLC and colorectal tumors that are improved by combination treatment with other agents[2].
| Animal Model: | KRAS G12C tumor-bearing nude mice (MIA PaCa-2 (PDAC); NCIH2122, LU99, HCC44, NCI-H2030 (NSCLC); and KYSE410 (esophageal cancer))[2] |
| Dosage: | 10, 30, 100 mg/kg |
| Administration: | Orally, daily for 14 days |
| Result: | Inhibited the growth of all models in a dose-dependent manner. |
| Animal Model: | Three KRAS G12C-mutated CDX models (LU99, NCI-H2030, and KYSE410)[2] |
| Dosage: | 100 mg/kg (JDQ443) + 7.5 mg/kg (TNO155) |
| Administration: | Orally, daily (JDQ443) or twice daily (TNO155), for 36 days |
| Result: | Combined with TNO155, showed either greater tumor efficacy compared with each agent alone (H2030, KYSE410) or a delayed time to tumor progression (LU99). |
![2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- Structure](/CAS/20211123/GIF/2653994-08-0.gif)
